Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Follow-Up Questions
Quel est le ratio P/E de Minerva Neurosciences Inc (NERV) ?
Le ratio P/E de Minerva Neurosciences Inc est de 12.287
Qui est le CEO de Minerva Neurosciences Inc ?
Dr. Remy Luthringer est le Executive Chairman of the Board of Directors de Minerva Neurosciences Inc, il a rejoint l'entreprise depuis 2014.
Quelle est la performance du prix de l'action NERV ?
Le prix actuel de NERV est de $3.73, il a decreased de 2.34% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Minerva Neurosciences Inc ?
Minerva Neurosciences Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Minerva Neurosciences Inc ?
La capitalisation boursière actuelle de Minerva Neurosciences Inc est de $26.0M
Est-ce que Minerva Neurosciences Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Minerva Neurosciences Inc, y compris 0 achat fort, 0 achat, 3 maintien, 1 vente et 0 vente forte